Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.41 |
| ▸ | WEE1 | P30291 | 4/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27248322 | 0.92 | L3MBTL1 (0.52) | L3MBTL1LMNABTKPRKD3TGFBR1 | |
| SCHEMBL27429930 | 0.87 | L3MBTL1 (0.60) | L3MBTL1LMNABTKPRKD3WEE1 | |
| SCHEMBL27248309 | 0.86 | SRC (0.52) | L3MBTL1LMNABTKPRKD3TGFBR1 | |
| SCHEMBL23867532 | 0.76 | SRC (0.53) | SRCHTR2AHTR2C | |
| SCHEMBL27429988 | 0.76 | HTR2C (0.61) | BLMHTR2AHTR2C | |
| SCHEMBL27248311 | 0.75 | HPGD (0.58) | L3MBTL1ABL1JAK2JAK3BLM | |
| SCHEMBL17716933 | 0.75 | HTR2C (0.50) | L3MBTL1LMNATRPV1HTR2AHTR2C | |
| SCHEMBL27248392 | 0.74 | HPGD (0.50) | BTKABL1PRKD3WEE1ALK | |
| SCHEMBL27429695 | 0.74 | HRH4 (0.49) | L3MBTL1BTKABL1AURKANTRK1 | |
| SCHEMBL27429987 | 0.74 | MAPT (0.48) | L3MBTL1LMNAABL1ROCK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199624-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | MSH2, KRAS, CHAMP1 | L3MBTL1 1129/4885LMNA 1270/4885BTK 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.